Rare disease and complex therapy pharmacy solutions provider Orsini announced on Monday that that it is now distributing biotechnology company BridgeBio's ATTRUBY (acoramidis), an orally administered treatment for cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).

ATTRUBY, a near-complete (greater than or equal to 90%) stabiliser of transthyretin, is intended for the treatment of adults with ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalisation.

Under the agreement, the therapy becomes part of Orsini's Cardiology Center of Excellence, and patients will be supported by the company's dedicated ATTR-CM Care Team.

Darin DeCarlo, Orsini's chief growth officer, said: "Orsini is deeply embedded in the cardiomyopathy space, having supported patients suffering from the disorder for over five years. Our partnership with BridgeBio offers us a tremendous opportunity to bring new hope to the patients we serve."